CALGARY, Nov. 15 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the company at Toronto CFA Society on Tuesday, November 20, 2007. The event is being held at the National Club, 303 Bay Street, Toronto at 7:45 a.m.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com
About Toronto CFA Society
Society membership is comprised of portfolio managers, investment analysts, corporate finance executives, academics, and other investment professionals who practice in a variety of fields, including investment counseling and management, banking, insurance, investment banking and brokerage firms, government agencies, regulators, and the financial media. Over 90% of members have a CFA designation.
The presentation times are subject to change. This release and the
presentation related thereto contain forward-looking statements which
involve known and unknown risks, delays, uncertainties and other factors
not under the Company's control and which may cause actual results,
performance or achievements of the Company to be materially different from
the results, performance or expectations implied by these forward-looking
statements. Such risks and uncertainties include, among others, the
efficacy of REOLYSIN(R) as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to the
research and development of pharmaceuticals and uncertaint
|SOURCE Oncolytics Biotech Inc.|
Copyright©2007 PR Newswire.
All rights reserved